Mariana Nacht
Keine laufenden Positionen mehr
Profil
Mariana Nacht worked as Vice President & Head-Biology at Padlock Therapeutics, Inc. from 2014 to 2016.
She then worked as Vice President-Cancer Biology at Kdac Therapeutics, Inc. from 2017 to 2018.
In 2018, she became the Chief Scientific Officer at Vivid Biosciences LLC until 2019.
From 2019 to 2020, she worked as the Chief Scientific Officer at Cereius, Inc. In 2020, she became the Chief Scientific Officer at LogicBio Therapeutics, Inc. Dr. Nacht holds a doctorate degree from the University of Pennsylvania and an undergraduate degree from Tufts University.
Ehemalige bekannte Positionen von Mariana Nacht
| Unternehmen | Position | Ende |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 16.11.2022 |
Cereius, Inc.
 Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2020 |
| Vivid Biosciences LLC | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2019 |
| Kdac Therapeutics, Inc. | Corporate Officer/Principal | 01.01.2018 |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.07.2016 |
Ausbildung von Mariana Nacht
| University of Pennsylvania | Doctorate Degree |
| Tufts University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Cereius, Inc.
Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Health Technology |
| Kdac Therapeutics, Inc. | |
| Vivid Biosciences LLC |
